Watch for the supplemental NDA filing for aficamten in nHCM expected in Q4 2026 and the Type II Variation in the EU in early 2027, which could expand the addressable market. Also monitor MYQORZO launch momentum and international expansion progress.
Drug in focus
CYTK drug pipeline →MYQORZO
▲ Bullish Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and commercializing in the U.S. (since December 2025) and Canada (October 2026). A label expansion decision from the FDA is expected November 14, 2026. A supplemental NDA for non-obstructive HCM is planned for submission in Q4 2026, with potential approval in 2027. EU submission is planned for early 2027.
- Next catalyst
- None dated
What to watchThe FDA decision on the MAPLE-HCM sNDA is due tomorrow, November 14, 2026. An approval would expand the label to include data showing aficamten's superiority over metoprolol, potentially strengthening the drug's positioning against standard-of-care beta blockers and BMS's Camzyos. A Complete Response Letter would be a negative surprise given the positive Phase 3 data. Separately, the supplemental NDA for non-obstructive HCM (ACACIA-HCM) is expected to be submitted in Q4 2026, which could be the next major catalyst.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $55.55entry
- T+1 · 11d ago −3.35%α −3.66% · $53.69
- T+5 · 5d ago +1.10%α −2.19% · $56.16
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cytokinetics reported Q3 2026 revenue of $47.6M, driven by $44.5M in MYQORZO net product revenue, beating the $42.3M consensus. EPS of -$1.37 beat the -$1.41 consensus. The company reaffirmed full-year 2026 guidance and plans to file a supplemental NDA for aficamten in non-obstructive HCM in Q4 2026.
Key Financial Metrics
Key Facts
- Total revenues $47.6M vs $1.9M YoY, consensus $42.3M
- MYQORZO net product revenue $44.5M ($43.1M U.S., $1.4M Europe)
- EPS -$1.37 vs consensus -$1.41 (beat)
- Net loss $190.1M vs $306.2M YoY
- Cash, equivalents and investments $1.6B as of Sep 30, 2026
- Reaffirmed FY2026 GAAP combined R&D and SG&A expense guidance $860M-$890M
- Plan to file supplemental NDA for aficamten in nHCM in Q4 2026
- Plan to launch MYQORZO in UK in Q4 2026
Financial Impact
Revenue beat consensus by $5.3M (12.5%); EPS beat by $0.04 (2.8%); net loss improved $116.1M YoY
Risk Factors
- Regulatory approval for nHCM indication not guaranteed; FDA may require additional trials or impose restrictions
- Commercial launch execution and market adoption of MYQORZO may not sustain current momentum
- Cash burn remains high; $1.6B cash provides runway but ongoing losses require future funding
- Competition from other cardiac myosin inhibitors and existing therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3395757 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Viewing Entry $55.55 Now $53.17 −4.28% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers